# Sophie Marguet

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sophie-marguet/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,067 |
| Field | Head and Neck Cancer Studies |
| h-index | 11 |
| i10-index | 12 |
| Last Known Institution | DATA4 (France) |
| OpenAlex ID | https://openalex.org/A5051723985 |
| ORCID iD | 0000-0001-6458-6889 |
| Works | 20 |

## Researcher papers

- [Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis](https://scholariq.org/papers/chemotherapy-and-radiotherapy-in-nasopharyngeal-carcinoma-an-update-of-the-mac/)
- [What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis](https://scholariq.org/papers/what-is-the-best-treatment-of-locally-advanced-nasopharyngeal-carcinoma-an/)
- [Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/prognostic-effect-of-tumor-lymphocytic-infiltration-in-resectable-non-small-cell/)
- [Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection](https://scholariq.org/papers/subtype-classification-of-lung-adenocarcinoma-predicts-benefit-from-adjuvant/)
- [Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis](https://scholariq.org/papers/surrogate-end-points-for-overall-survival-in-loco-regionally-advanced/)
- [Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer](https://scholariq.org/papers/progression-free-survival-as-surrogate-end-point-for-overall-survival-in/)
- [Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer](https://scholariq.org/papers/cost-effectiveness-of-molecular-profiling-for-adjuvant-decision-making-in/)
- [Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma](https://scholariq.org/papers/surrogate-end-points-for-overall-survival-in-loco-regionally-advanced-2/)
- [How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models](https://scholariq.org/papers/how-to-model-survival-in-cost-effectiveness-analysis-differences-between-markov/)
- [Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort](https://scholariq.org/papers/treatment-resistant-depression-in-a-real-world-setting-first-interim-analysis-of/)
- [Epidemiology, disease evolution and economic burden of amyotrophic lateral sclerosis in France using the French national health data system](https://scholariq.org/papers/epidemiology-disease-evolution-and-economic-burden-of-amyotrophic-lateral/)

## Researcher topics

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Head and Neck Surgical Oncology](https://scholariq.org/topics/head-and-neck-surgical-oncology/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [DATA4 (France)](https://scholariq.org/institutions/data4-france/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.